The Journal for ImmunoTherapy of Cancer (JITC) welcomes submissions in the following areas and related topics:
Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the anti-tumor immune response, and oncolytic viruses.
Reports on unusual or unexpected clinical cases that expand the field of general medical knowledge. Includes information on an unexpected association between diseases or symptoms, an unexpected event in the course of observing or treating a patient, findings that shed new light on the possible pathogenesis of the disease or an adverse effect, unique or rare features of the disease, and/or a unique therapeutic approach.
First-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcome, combination therapies, and cell therapies.
Announcements and updates of cancer immunotherapy clinical trials in progress. Includes perspectives and implications of late stage pivotal clinical trials results and new regulatory approvals. Articles may also focus on other pertinent regulatory issues to help define a road map for navigating the clinical trial landscape.
Reaction to and/or perspectives on significant events in the field in the basic science area. May address a critical challenge, elaborate or extend a conversation of a focal article, provide an application of a theoretical perspective, or shed light on a particular issue in the field.
Predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies, clinical trial analyses and identification of novel immune biomarkers.
Fact/data-driven works that cumulate several articles of importance on a particular subject or research area in a review format with the goal of providing the “state of the art” in the field. Includes recent major advances and discoveries, significant gaps in the research, current debates, and/or ideas of where research might go next.
Content freely available upon publication.
Articles published within 2-4 weeks of acceptance.
Featured in six major indexing resources including:
Published by BioMed Central, a member of the Committee on Publishing Ethics.
Monthly JITC Digest sent to global experts.
Recipients Receive $1,000* and recognition at SITC's Annual Meeting.
*Papers published between August 2016 to September 2017 authored by SITC members are eligible for nomination for awards. Papers on which the first or senior author is a SITC member are eligible for consideration. Join SITC, renew your membership, or check your current membership status.
Submit your Manuscript to JITC
It is the recent modest single agent activity of programmed death-ligand 1 and programmed death receptor-1 antibodies for those with breast cancer that is generating hope for use of immunotherapy in breast cancer. To ponder in the meantime, in preparation ...
FYI for those in the Tampa, FL area. Emerging Opportunities--Enhancing Awareness of Clinical Trials The 2017 Breast Immune-Oncology Conference is being held Sat., Oct. 7th at Moffitt Cancer Center. There will be a free companion Patient Advocacy Program ...
DC immunotherapy makes use of the patient's own DCs to activate cancer cell elimination.There is an inherent danger, for example, that the effect of CTLA 4 blockade is not restricted to tumor-specific T cells. resulting in immune-related toxicities that ...
From Bedside to Bench and Back Again | Boston on September 26-27, 2017 ------------------------------ Joseph Murphy PhD Director Charles River Laboratories Quincy MA ----------------------------
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org